The Canadian subsidiary of engineering and construction firm Fluor Daniel of Irvine, CA, has won a contract to process medical radioisotopes produced by the Maple reactor complex being built by Atomic Energy of Canada (AECL). Fluor Daniel Canada will
The Canadian subsidiary of engineering and construction firm Fluor Daniel of Irvine, CA, has won a contract to process medical radioisotopes produced by the Maple reactor complex being built by Atomic Energy of Canada (AECL). Fluor Daniel Canada will construct a processing facility near the Maple complex to house hot cells, which are used for the separation of isotopes.
AECL is building the Maple reactors to provide a stable supply of radioisotopes such as molybdenum, the raw material for technetium-99m, a commonly used radioisotope in nuclear medicine studies. The age of the existing AECL reactor that is being used to produce molybdenum has concerned nuclear medicine physicians, and a labor dispute at AECL caused a brief shutdown of molybdenum shipments last summer (SCAN 7/9/97). The Maple reactors are scheduled to be completed by 1999, with medical isotope production beginning some time after that.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.